Kobayashi Pharmaceutical Co., Ltd. (TYO: 4967)

Kobayashi Pharmaceutical Income Statement

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	168,799	173,455	166,258	155,252	150,514	168,052
Revenue Growth (YoY)	-1.34%	4.33%	7.09%	3.15%	-10.44%	0.34%
Cost of Revenue	77,831	77,079	73,927	66,478	65,248	64,705
Gross Profit	90,968	96,376	92,331	88,774	85,266	103,347
Selling, General & Admin	54,461	57,457	53,902	52,072	50,114	67,850
Research & Development	9,004	9,004	8,327	7,522	7,338	7,110
Other Operating Expenses	930	930	767	718	729	744
Operating Expenses	67,762	70,749	65,825	62,823	59,457	77,138
Operating Income	23,206	25,627	26,506	25,951	25,809	26,209
Interest Expense	-29	-29	-18	-18	-21	-20
Interest & Investment Income	799	762	578	588	747	984
Currency Exchange Gain (Loss)	-302	40	231	481	-216	-150
Other Non Operating Income (Expenses)	740	930	983	1,011	1,407	828
EBT Excluding Unusual Items	24,414	27,330	28,280	28,013	27,726	27,851
Gain (Loss) on Sale of Investments	5	436	-89	84	261	315
Gain (Loss) on Sale of Assets	-61	-59	-52	-70	-64	-140
Asset Writedown	-59	-59	-69	-309	-1,122	-1,663
Other Unusual Items	-10,599	-89	-121	-83	-166	441
Pretax Income	13,700	27,559	27,949	27,635	26,635	26,804
Income Tax Expense	3,516	7,221	7,927	7,920	7,430	7,665
Earnings From Continuing Operations	10,184	20,338	20,022	19,715	19,205	19,139
Net Income	10,184	20,338	20,022	19,715	19,205	19,139
Net Income to Common	10,184	20,338	20,022	19,715	19,205	19,139
Net Income Growth	-51.55%	1.58%	1.56%	2.66%	0.34%	6.19%
Shares Outstanding (Basic)	75	76	77	78	78	78
Shares Outstanding (Diluted)	75	76	77	78	78	78
Shares Change (YoY)	-2.24%	-1.67%	-1.27%	-0.05%	-0.32%	-0.82%
EPS (Basic)	136.67	268.16	259.61	252.35	245.70	244.07
EPS (Diluted)	136.67	268.16	259.59	252.35	245.70	244.07
EPS Growth	-50.44%	3.30%	2.87%	2.71%	0.67%	7.07%
Free Cash Flow	-	5,604	17,167	18,756	20,191	15,710
Free Cash Flow Per Share	-	73.89	222.57	240.08	258.32	200.34
Dividend Per Share	101.000	101.000	90.000	83.000	77.000	73.000
Dividend Growth	6.32%	12.22%	8.43%	7.79%	5.48%	10.61%
Gross Margin	53.89%	55.56%	55.53%	57.18%	56.65%	61.50%
Operating Margin	13.75%	14.77%	15.94%	16.72%	17.15%	15.60%
Profit Margin	6.03%	11.73%	12.04%	12.70%	12.76%	11.39%
Free Cash Flow Margin	-	3.23%	10.33%	12.08%	13.41%	9.35%
EBITDA	29,787	31,684	31,864	30,786	29,915	30,336
EBITDA Margin	17.65%	18.27%	19.17%	19.83%	19.88%	18.05%
D&A For EBITDA	6,581	6,057	5,358	4,835	4,106	4,127
EBIT	23,206	25,627	26,506	25,951	25,809	26,209
EBIT Margin	13.75%	14.77%	15.94%	16.72%	17.15%	15.60%
Effective Tax Rate	25.66%	26.20%	28.36%	28.66%	27.90%	28.60%
Advertising Expenses	-	23,038	22,389	22,499	21,608	35,414

Source: S&P Capital IQ. Standard template. Financial Sources.